Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Orismilast - UNION Therapeutics

Drug Profile

Orismilast - UNION Therapeutics

Alternative Names: IBI-353; LEO32731; LP-0058; UNI-50001; UNI-50002

Latest Information Update: 10 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator LEO Pharma
  • Developer Innovent Biologics; LEO Pharma; UNION Therapeutics
  • Class Anti-inflammatories; Antipsoriatics; Benzodioxoles; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Pyridines; Skin disorder therapies; Small molecules; Spiro compounds
  • Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Hidradenitis suppurativa; Plaque psoriasis; Ulcerative colitis

Most Recent Events

  • 04 Jun 2024 UNION Therapeutics schedules an End of Phase 2 meeting with the US FDA for orismilast development program into phase III trial in Atopic dermatitis
  • 04 Jun 2024 UNION therapeutics completes the phase-II ADESOS trial in Atopic dermatitis in Poland, Germany, USA, Hungary (PO) (NCT05469464)
  • 04 Jun 2024 UNION therapeutics plans a phase III trial in Atopic dermatitis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top